玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析

doi:10.6040/j.issn.1673-3770.0.2015.302

摘要/Abstract

摘要： 目的探讨玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿(ME)的临床疗效及安全性。方法选取BRVO继发ME患者33例(38眼)为研究对象,均经玻璃体腔内注射康柏西普眼用注射液0.05 mL。随访6个月期间,至少每个月检查1次,根据光学相干断层扫描(OCT)测量黄斑中心凹厚度以判断是否行再次注射。比较治疗前及治疗后1、3个月最佳矫正视力(BCVA),治疗前及治疗后1个月OCT结果,并观察治疗后1个月内并发症的发生情况。结果最小分辨率视力(VA)对数为(0.59±0.21),首次注射后1个月显著改善至(0.35±0.12)(P<0.01)。治疗前及治疗后1、3个月BCVA比较差异有统计学意义(P<0.05),且治疗后3个月BCVA明显高于治疗前(P<0.05)。治疗前及治疗后1个月视网膜黄斑中心凹厚度比较差异有统计学意义(P<0.05)。治疗后1个月内仅5例(15.15%)发生眼压一过性增高,未见其他明显眼不良事件。结论基于OCT的玻璃体腔内注射康柏西普治疗BRVO继发ME短期疗效确切,且具有较好的安全性。

关键词: 玻璃体, 黄斑水肿, 视网膜分支静脉阻塞, 康柏西普, 光学相干断层扫描

Abstract: Objective To explore the clinical efficacy and safety of intravitreal injection of conbercept in the treatment of macular edema(ME)secondary to branch retinal vein occlusion(BRVO). Methods A total of 33 patients(38 eyes)with ME secondary to BRVO were selected as research objects, and injected Conbercept Ophthalmic Injection 0.05 mL through vitreous cavity. The optic examination was conducted at least once a month during 6-mongh follow-up. The central foveal thickness was measured to judge whether the injection was given again using optical coherence tomography(OCT). The best corrected visual acuity(BCVA)before and 1, 3 months after treatment as well as OCT results before and 1 month after treatment were compared, and the complications within 1 month after treatment were observed. Results The logarithm of minimum visual resolution(VA)was(0.59±0.21), and improved to(0.35±0.12)after the first injection(P<0.01). There was statistical significance regarding the BCVA before and 1, 3 months after treatment(P<0.05), and the BCVA 3 months after treatment was dramatically higher than that before treatment(P<0.05). The difference was statistically significant regarding the central foveal thickness of retina before and 1 month after treatment(P<0.05). Within 1 month after treatment, only 5 patients(15.15%)suffered from transient increase of intraocular pressure, no other eye-related events occurred. Conclusion For ME secondary to BRVO, intravitreal injection of conbercept based on OCT has definite short-term efficacy and better safety.

Key words: Conbercept, Macular edema, Branch retinal vein occlusion, Optical coherence tomography

中图分类号:

R774

邢凯,亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 80-82.

XING Kai, KANG Zefeng. Clinical analysis on intravitreal injection of conbercept in the treatment of macular edema secondary to branch retinal vein occlusion.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(1): 80-82.

参考文献

[1] 艾伦(美), 姚静. 美国威尔斯眼科医院临床眼科图谱和精要: 视网膜病[M]. 上海:上海科学技术出版社, 2005: 101.
[2] 张承芬. 眼底病学[M]. 2版.北京:人民卫生出版社, 2010: 560-575.
[3] 张菁, 蔡小军, 陈晓敏, 等. 玻璃体腔注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察[J]. 中华眼底病杂志, 2015, 31(1):22-26. ZHANG Jing, CAI Xiaojun, CHEN Xiaomin, et al. A prospective randomized clinical trial on intravitreal injection of Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Chin J Ocular Fundus Dis, 2015, 31(1):22-26.
[4] Donati S, Barosi P, Bianchi M, et al. Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion[J]. Eur J Ophthalmol, 2012, 22(4):607-614.
[5] Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J]. PLoS ONE, 2013, 8(8):e70544.
[6] Wu Z, Zhou P, Li X, et al. Structural characterization of a recombinant fusion protein by instrumental analysis and molecular modeling[J]. PLoS ONE, 2013, 8(3):e57642.
[7] 曲毅, 魏奉才. Wills眼科手册[M].5版. 济南:山东科学技术出版社, 2009: 434.
[8] 毕燃, 贾彩华, 于越, 等. 康柏西普治疗视网膜静脉阻塞黄斑水肿的临床观察[J].赤峰学院学报(自然科学版), 2014, 23:71-73. BI Ran, JIA Caihua, YU Yue, et al. Clinical observation of conbercept in the treatment of patients with macular edema secondary to branch retinal vein occlusion[J]. J Chifeng Univ(Nat Sci Ed), 2014, 23:71-73.
[9] Chen C H, Chen Y H, Wu P C, et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection[J]. Chang Gung Med J, 2010, 33(4):424-435.
[10] Feng J, Zhao T, Zhang Y, et al. Differences in aqueous concentrations of cytokines In macular edema secondary to branch and central retinal vein occlusion[J]. PLoS ONE, 2013, 8(7):e68149.
[11] Pielen A, Mirshahi A, Fehgen N, et al. Ranibizumab for branch retinal vein occlusion associated macular edema study(RABAMES): six-month results of a prospective randomized clinical trial[J]. Acta Ophthalmol, 2015, 93(1):e29-37.
[12] Tsagkataki M, Papathomas T, Lythgoe D, et al. Twenty-four-month results of intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion[J]. Semin Ophthalmol, 2015, Aug 21:1-8, [Epub ahead of print].
[13] Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion[J]. Br J Ophthalmol, 2014, 98(2):195-199.
[14] 舒智宇. 康柏西普治疗视网膜静脉阻塞黄斑水肿的临床分析[J]. 延边医学, 2015, 12:47-48. SHU Zhiyu. Clinical analysis of conbercept for treating macular edema secondary to branch retinal vein occlusion[J]. Yanbian Med J, 2015, 12:47-48.

相关文章 15

[1]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术治疗孔源性视网膜脱离的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(5): 92-94.
[2]	周学义,李一鸣,王美菊,张苑苑,张历浊. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89.
[3]	靳琳,潘庆敏,胡磊. 玻璃体腔注射雷珠单抗治疗CSME及NCSME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 96-98.
[4]	严槟,尹小芳,叶祖科,卢彦,洪剑威. 玻璃体腔注射雷珠单抗联合GLP治疗BRVO-ME的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 110-113.
[5]	焦芮,韩克阳,王淑雅综述, 赵博军审校. 光学相干断层扫描技术在非动脉炎性前部缺血性视神经病变中的诊断现状[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 119-122.
[6]	王旭川,盛艳娟,王玉. 非外伤性玻璃体积血的病因及手术疗效分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 107-109.
[7]	韩克阳,王淑雅,焦芮,于贝贝综述, 赵博军审校. 视网膜静脉阻塞的发病机制及黄斑水肿的抗-VEGF治疗[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 123-126.
[8]	严晓腾,冯军,康欣乐. 玻璃体腔注射康柏西普治疗视网膜静脉阻塞继发黄斑水肿的临床观察[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 105-108.
[9]	邵娜,张晗. 糖尿病患者行白内障超声乳化术后视力及眼底的变化[J]. 山东大学耳鼻喉眼学报, 2016, 30(1): 83-87.
[10]	胡新苗. 视网膜光凝联合玻璃体切除术治疗增生性糖尿病视网膜病变的有效性及安全性[J]. 山东大学耳鼻喉眼学报, 2015, 29(6): 74-77.
[11]	柴雪荣, 张士玺, 陶钰, 申家泉. 玻璃体腔注射雷珠单抗联合小梁切除术及全视网膜光凝治疗新生血管性青光眼的效果评价[J]. 山东大学耳鼻喉眼学报, 2015, 29(3): 72-75.
[12]	汪新, 魏伟. 中药“益视合剂”辅助治疗儿童弱视[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 56-59.
[13]	严晓腾, 冯军, 康欣乐. 曲安奈德玻璃体腔注射联合格栅样光凝治疗囊样黄斑水肿[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 60-63.
[14]	刘海洋, 李甦雁, 张正培, 范巍. 改良膜分割与双手膜清除技术在23G玻璃体手术治疗增殖性糖尿病视网膜病变中的对比[J]. 山东大学耳鼻喉眼学报, 2015, 29(1): 52-55.
[15]	孙洪义, 张晗. 2型糖尿病患者超声乳化白内障摘除并人工晶体植入手术后黄斑区光学相干断层扫描改变[J]. 山东大学耳鼻喉眼学报, 2014, 28(6): 72-76.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed